FDAnews Device Daily Bulletin
Medical Devices / Regulatory Affairs

Functional Neuromodulation Announces New CEO

Jan. 29, 2019
A A

Functional Neuromodulation, a devicemaker with a focus an implantable deep brain stimulation (DBS) therapy, named Todd Langevin as its new CEO.

Langevin previously held senior leadership roles at other medical device companies such as Medtronic and CVRx. During his twenty years at Medtronic, he served as vice president and general manager of the company’s DBS movement disorders business.

Functional Neuromodulation’s work with DBS therapy is intended to help treat patients with mild Alzheimer’s disease through neural stimulation.

View today's stories